Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 04 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Rectal NSAIDs are superior to pancreatic duct stents in preventing pancreatitis after ERCP

Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography, reports the most recent issue of the Clinical Gastroenterology & Hepatology.

News image

Placement of pancreatic duct stents prevents pancreatitis after endoscopic retrograde cholangiopancreatography.

There is evidence that rectal administration of nonsteroidal anti-inflammatory drugs also prevents post-endoscopic retrograde cholangiopancreatography pancreatitis, but the 2 approaches alone have not been compared directly.

Dr Ali Akbar from Minnesota, USA conducted a network meta-analysis to indirectly compare the efficacies of these procedures.

The team searched PubMed and Embase by 2 independent reviewers to identify full-length clinical studies, published in English, investigating use of pancreatic duct stent placement, and rectal nonsteroidal anti-inflammatory drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis.

The team identified 29 studies.

The researchers used network meta-analysis to compare rates of post-endoscopic retrograde cholangiopancreatography pancreatitis among patients who received only rectal nonsteroidal anti-inflammatory drugs, only pancreatic duct stents, or both.

The combination of rectal NSAIDs with rectal stents was not superior to either approach alone
Clinical Gastroenterology and Hepatology

Placement of pancreatic duct stents and rectal administration of nonsteroidal anti-inflammatory drugs were each superior to placebo in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.

The combination of rectal nonsteroidal anti-inflammatory drugs and stents was not superior to either approach alone.

The doctors assessed that the pooled results showed that rectal nonsteroidal anti-inflammatory drugs alone were superior to pancreatic duct stents alone in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.

Dr Akbar's team commented, "Based on a network meta-analysis, rectal nonsteroidal anti-inflammatory drugs alone are superior to pancreatic duct stents alone in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis, and should be considered first-line therapy for selected patients."

"However, these findings were limited by the small number of studies assessed, potential publication bias, and the indirect nature of the comparison."

"High-quality, randomized, controlled trials are needed to compare these 2 interventions and confirm these findings."

Clin Gastroenterol and Hepatol 2013: 11(7) :778-783
15 July 2013

Go to top of page Email this page Email this page to a colleague

 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants
 08 November 2016 
NSAIDS and risk of Barrett’s
 08 November 2016 
Ferritin levels and NAFLD mortality
 08 November 2016 
Alarms in the diagnosis of colorectal cancer
 07 November 2016 
BMI and fibrosis regression during Hep B
 07 November 2016 
Prognosis and biliary tract malignancies
 07 November 2016 
Post-colonoscopy colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us